NEW YORK (GenomeWeb News) – Eutropics said today that it will use its companion diagnostic methodology to help Tolero Pharmaceuticals develop therapeutics for hematological malignancies.

Under the terms of the agreement, Eutropics will use its Praedicare-Dx biomarker platform to support the development of Tolero's alvocidibm, a Phase III compound that has demonstrated clinical activity in patients with acute myelogenous leukemia and chronic lymphocytic leukemia.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.